ProCE Banner Activity

Improving Outcomes for Relapsed/Refractory PTCL

Slideset Download
Download these slides from an ASH satellite symposium to learn how to improve outcomes for relapsed/refractory PTCL using biomarkers and targeted therapy.

Released: December 09, 2021

Expiration: December 08, 2022

No longer available for credit.

Share

Faculty

Steven M. Horwitz

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Kyowa Kirin Inc

Seagen Inc.

Takeda Oncology

Faculty Disclosure

Primary Author

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Steven M. Horwitz, MD, has disclosed that he has received consulting fees from Acrotech Biopharma, C4 Therapeutics, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Seattle Genetics, SecuraBio, Shoreline Biosciences, Takeda, Trillium, Tubulis, and Vividion; funds for research support from ADC Therapeutics, Affimed, Celgene, Daiichi Sankyo, Kyowa Hakko Kirin, Millennium/Takeda, Seattle Genetics, Trillium, and Verastem/SecuraBio.